Velvet Therapeutics

Executive Summary

Velvet Therapeutics is an early-stage biotechnology company pioneering a non-viral platform for in vivo delivery of chimeric antigen receptor (CAR) constructs to multiple immune cell types. Founded in 2021 and based in Cambridge, MA, the company combines minicircle DNA with amino acid-based nanoparticles to achieve redosable, non-integrating immune cell reprogramming. This approach aims to overcome key limitations of viral vectors, such as immunogenicity, packaging constraints, and inability to redose, potentially enabling safer and more effective cell therapies for oncology and autoimmune indications. While still preclinical, Velvet's technology has the potential to expand CAR therapy to solid tumors and reduce manufacturing complexity by eliminating ex vivo cell manipulation. The company has not disclosed funding rounds or partnerships, but its non-viral platform is a compelling alternative to conventional CAR-T approaches, warranting attention as it progresses toward IND-enabling studies.

Upcoming Catalysts (preview)

• Q1 2027Preclinical Proof-of-Concept Data Release40% success
• H2 2026Series A Financing Announcement50% success
• Q3 2026Partnership with Academic or Pharma Partner30% success